Conditions: Breast Cancer; Ovarian Cancer; Endometrial Cancer; PIK3CA Mutation; HER2- Negative Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor; Hormone Receptor Positive Tumor; Cervical Cancer
Interventions: Drug: RGT-490
Sponsors: Regor Pharmaceuticals Inc.
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
